Brief: Calmark Comments On The Effects From COVID-19

Calmark Sweden AB

26/03/2020 13:01

March 26 (Reuters) - Calmark Sweden AB  CALMAb.TE :
    * CALMARK COMMENTS ON THE EFFECTS FROM COVID-19 AND
ANNOUNCES
UPDATED TIMETABLE FOR CLINICAL TRIAL AT SÖDERSJUKHUSET
    * UP UNTIL NOW, CALMARK'S DEVELOPMENT PROJECT HAS NOT BEEN
NEGATIVELY IMPACTED BY COVID-19 OUTBREAK
    * WORK IS PROGRESSING AT BEST POSSIBLE PACE
    * IT IS DIFFICULT TO ASSESS TODAY HOW REPRIORITIZATIONS AND
REORGANIZATIONS WILL AFFECT COMPANY AND STUDY
    * AT PRESENT, IT IS DIFFICULT TO ASSESS CONSEQUENCES OF
COVID-19
FOR COMPANY, BOTH WITH REGARD TO OUTBREAK ITSELF AND DECISIONS
THAT FOLLOW IN ITS WAKE
    * CALMARK'S LIQUIDITY IS ABUNDANT FOR TIME BEING THANKS TO
DIRECTED RIGHTS ISSUE WHICH WAS CARRIED OUT IN DECEMBER 2019
    * TEMPORARY MODIFICATIONS MADE TO COMPANY'S SALES PROCESS
MAY
AFFECT PACE OF MARKET LAUNCH

Source text for Eikon:  ID:nWkr1NYh97 
Further company coverage:  CALMAb.TE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))